Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers

Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xabier Mielgo-Rubio, Virginia Calvo, Javier Luna, Jordi Remon, Margarita Martín, Pedro Berraondo, José Ramón Jarabo, Oliver Higuera, Esther Conde, Javier De Castro, Mariano Provencio, Florentino Hernando Trancho, Fernando López-Ríos, Felipe Couñago
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI AG 2020-11-01
Colección:Cancers
Materias:
immunotherapy
early-stage
non-small cell lung cancer
biomarkers
PD-1
nivolumab
Acceso en línea:https://www.mdpi.com/2072-6694/12/11/3459
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares